Allergy Therapeutics plc

AIM:AGY Voorraadrapport

Marktkapitalisatie: UK£262.2m

Allergy Therapeutics Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Allergy Therapeutics's earnings have been declining at an average annual rate of -72.7%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been declining at an average rate of 5.2% per year.

Belangrijke informatie

-72.7%

Groei van de winst

-65.9%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie14.1%
Inkomstengroei-5.2%
Rendement op eigen vermogen-189.8%
Nettomarge-94.3%
Laatste winstupdate31 Dec 2023

Recente prestatie-updates uit het verleden

Recent updates

Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet

Sep 12
Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet

Allergy Therapeutics plc's (LON:AGY) 28% Share Price Surge Not Quite Adding Up

May 21
Allergy Therapeutics plc's (LON:AGY) 28% Share Price Surge Not Quite Adding Up

Allergy Therapeutics plc (LON:AGY) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Dec 18
Allergy Therapeutics plc (LON:AGY) Surges 28% Yet Its Low P/S Is No Reason For Excitement

Opbrengsten en kosten

Hoe Allergy Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

AIM:AGY Opbrengsten, kosten en inkomsten (GBP Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
31 Dec 2353-504523
30 Sep 2356-474722
30 Jun 2360-434920
31 Mar 2362-364920
31 Dec 2264-294819
30 Sep 2268-214817
30 Jun 2273-144716
31 Mar 2276-104714
31 Dec 2179-54813
30 Sep 2182-14713
30 Jun 218434613
31 Mar 218354511
31 Dec 20827459
30 Sep 20807459
30 Jun 20787459
31 Mar 207884511
31 Dec 197784512
30 Sep 197664513
30 Jun 197434513
31 Mar 197304414
31 Dec 1873-34315
30 Sep 1871-54316
30 Jun 1868-84316
31 Mar 1867-54214
31 Dec 1766-34211
30 Sep 1765-34110
30 Jun 1764-2419
31 Mar 1762-53911
31 Dec 1660-73714
30 Sep 1654-103415
30 Jun 1649-133016
31 Mar 1646-102912
31 Dec 1544-6289
30 Sep 1544-3286
30 Jun 15430273
31 Mar 15431273
31 Dec 14432263
30 Sep 14421263
30 Jun 14421263
31 Mar 14411253
31 Dec 13412253

Kwaliteitswinsten: AGY is currently unprofitable.

Groeiende winstmarge: AGY is currently unprofitable.


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: AGY is unprofitable, and losses have increased over the past 5 years at a rate of 72.7% per year.

Versnelling van de groei: Unable to compare AGY's earnings growth over the past year to its 5-year average as it is currently unprofitable

Winst versus industrie: AGY is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).


Rendement op eigen vermogen

Hoge ROE: AGY has a negative Return on Equity (-189.77%), as it is currently unprofitable.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden